We are live on ! Find out more
RPAM

Rhenman & Partners Asset Management Portfolio holdings

AUM $810M
1-Year Est. Return 30.2%
This Fund
S&P 500
This Quarter Est. Return
+17.86%
1 Year Est. Return
+30.2%
3 Year Est. Return
+116.38%
5 Year Est. Return
+153.13%
10 Year Est. Return
+962.25%
AUM
$345M
AUM Growth
+$3.48M
Cap. Flow
-$46.4M
Cap. Flow %
-13.44%
Top 10 Hldgs %
30.53%
Holding
110
New
11
Increased
34
Reduced
36
Closed
26

Top Buys

Rank Stock Value
1
GILD icon
Gilead Sciences
GILD
+$13.9M
2
CELG
Celgene Corp
CELG
+$10.8M
3
RCPT
RECEPTOS INC COM STK (DE)
RCPT
+$5.32M
4
REGN icon
Regeneron Pharmaceuticals
REGN
+$3.74M
5
MDVN
MEDIVATION, INC.
MDVN
+$3.4M

Top Sells

Rank Stock Value
1
UHS icon
Universal Health Services
UHS
+$10.3M
2
MDT icon
Medtronic
MDT
+$6.86M
3
ALKS icon
Alkermes
ALKS
+$6.27M
4
INCY icon
Incyte
INCY
+$4.12M
5
NPSP
NPS PHARMACEUTICALS INC
NPSP
+$4.03M

Sector Composition

Rank Sector Weight
1 Healthcare 80.57%
2 Consumer Staples 1.97%
3 Financials 1.39%
Name Market Value Portfolio Weight Shares or Principal Change
in Stake 		Capital Flow
LXRX icon
76
Lexicon Pharmaceuticals
LXRX
$1.1B
$1.45M 0.42%
227,829
+185,714
+441% +$1.5M
KERX
77
DELISTED
Keryx Biopharmaceuticals Inc
KERX
$1.28M 0.37%
90,424
-45,576
-34% -$706K
XNCR icon
78
Xencor
XNCR
$1.55B
$802K 0.23%
+50,000
New +$580K
BIND
79
DELISTED
BIND THERAPEUTICS INC
BIND
$721K 0.21%
133,535
+25,000
+23% +$187K
MTEM
80
DELISTED
Molecular Templates, Inc.
MTEM
$641K 0.19%
1,221
+484
+66% +$242K
ANTH
81
DELISTED
Anthera Pharmaceuticals, Inc.
ANTH
$632K 0.18%
50,000
– –
AFL icon
82
Aflac
AFL
$62.6B
– –
-64,000
Closed -$1.86M
BSX icon
83
Boston Scientific
BSX
$71.5B
– –
-214,000
Closed -$2.53M
CI icon
84
Cigna
CI
$74.6B
– –
-22,000
Closed -$2M
EXEL icon
85
Exelixis
EXEL
$13.4B
– –
-500,000
Closed -$765K
JNJ icon
86
CALL
Johnson & Johnson
JNJ
$625B
– –
-140,000
Closed -$14.9M
MASI
87
DELISTED
Masimo
MASI
– –
-135,000
Closed -$2.87M
MD icon
88
Pediatrix Medical
MD
$2.2B
– –
-44,000
Closed -$2.41M
SYK icon
89
Stryker
SYK
$130B
– –
-21,000
Closed -$1.7M
TEVA icon
90
Teva Pharmaceuticals
TEVA
$41.2B
– –
-59,000
Closed -$3.17M
UHS icon
91
Universal Health Services
UHS
$10.5B
– –
-98,700
Closed -$10.3M
VIRX
92
DELISTED
Viracta Therapeutics, Inc. Common Stock
VIRX
– –
-958
Closed -$1.44M
IMGN
93
DELISTED
Immunogen Inc
IMGN
– –
-180,000
Closed -$1.91M
INFI
94
DELISTED
Infinity Pharmaceuticals, Inc.
INFI
– –
-148,000
Closed -$1.99M
NUVA
95
DELISTED
NuVasive, Inc.
NUVA
– –
-54,000
Closed -$1.88M
SRNE
96
DELISTED
Sorrento Therapeutics, Inc.
SRNE
– –
-72,535
Closed -$328K
ECYT
97
DELISTED
Endocyte, Inc. Common Stock
ECYT
– –
-49,297
Closed -$300K
ESRX
98
DELISTED
Express Scripts Holding Company
ESRX
– –
-39,000
Closed -$2.75M
PRXL
99
DELISTED
Parexel International Corp
PRXL
– –
-34,000
Closed -$2.15M
AEGR
100
DELISTED
Aegerion Pharmaceuticals
AEGR
– –
-65,000
Closed -$2.17M
1 2 3
4
5

Similar funds

PS
Portfolio Strategies Monsey, New York $811M AUM 28.91% 1-Year Est. Return
ACM
Ashford Capital Management Wilmington, Delaware $809M AUM 35.1% 1-Year Est. Return
AR
Advisory Research Chicago, Illinois $813M AUM 36.71% 1-Year Est. Return
KCP
Kera Capital Partners San Jose, California $815M AUM 46.39% 1-Year Est. Return
BCM
Brigade Capital Management New York $806M AUM 20.71% 1-Year Est. Return
RIM
Redwood Investment Management Scottsdale, Arizona $805M AUM 15.01% 1-Year Est. Return
GCM
Glendon Capital Management Santa Monica, California $805M AUM 17.91% 1-Year Est. Return
CL
CVFG LLC Shelbyville, Indiana $804M AUM 27.61% 1-Year Est. Return

Rhenman & Partners Asset Management's Q4 2014 Portfolio in Review

As of Q4 2014, Rhenman & Partners Asset Management held 110 positions worth $345M, up 1% from $342M the previous quarter. Its ten largest holdings account for 31% of the portfolio.

Rhenman & Partners Asset Management withdrew a net $46.4M in Q4 2014, closing 26 positions and reducing 36 holdings. Its most notable exit was Universal Health Services, an estimated $10.3M position sold in full.

By sector, the portfolio is most concentrated in Healthcare at 81% of assets, up from 79% a quarter earlier, followed by Consumer Staples and Financials.

Against the trend, Rhenman & Partners Asset Management opened a new position in RECEPTOS INC COM STK (DE) worth $6.43M.

  • Rhenman & Partners Asset Management's largest Q4 2014 buy was RECEPTOS INC COM STK (DE): 52,526 shares worth $6.43M.
  • Rhenman & Partners Asset Management added most to Gilead Sciences in Q4 2014, an estimated $13.9M increase.
  • Rhenman & Partners Asset Management's biggest Q4 2014 reduction was Medtronic, cutting an estimated $6.86M.
  • Rhenman & Partners Asset Management fully exited Universal Health Services in Q4 2014, selling an estimated $10.3M.
  • Rhenman & Partners Asset Management's ten largest holdings make up 31% of its $345M portfolio in Q4 2014.
  • Rhenman & Partners Asset Management opened 11 new positions and closed 26 in Q4 2014.
  • Rhenman & Partners Asset Management's portfolio value rose 1% quarter-over-quarter to $345M.

Based on Rhenman & Partners Asset Management's 13F filing for Q4 2014, filed 9 Feb 2015.